(Reuters) - Gilead Sciences Inc (NASDAQ:GILD) said on Monday it has filed a marketing application with the U.S. Food and Drug Administration for its experimental COVID-19 drug remdesivir.
(Reuters) - Gilead Sciences Inc (NASDAQ:GILD) said on Monday it has filed a marketing application with the U.S. Food and Drug Administration for its experimental COVID-19 drug remdesivir.